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Abstract
Background: Amyloid fibril formation is the hallmark of many human diseases, including Alzheimer’s disease, type II
diabetes and amyloidosis. Amyloid fibrils deposit in the extracellular space and generally co-localize with the
glycosaminoglycans (GAGs) of the basement membrane. GAGs have been shown to accelerate the formation of amyloid
fibrils in vitro for a number of protein systems. The high number of data accumulated so far has created the grounds for the
construction of a database on the effects of a number of GAGs on different proteins.
Methodology/Principal Findings: In this study, we have constructed such a database and have used a computational
approach that uses a combination of single parameter and multivariate analyses to identify the main chemical factors that
determine the GAG-induced acceleration of amyloid formation. We show that the GAG accelerating effect is mainly
governed by three parameters that account for three-fourths of the observed experimental variability: the GAG sulfation
state, the solute molarity, and the ratio of protein and GAG molar concentrations. We then combined these three
parameters into a single equation that predicts, with reasonable accuracy, the acceleration provided by a given GAG in a
given condition.
Conclusions/Significance: In addition to shedding light on the chemical determinants of the protein:GAG interaction and to
providing a novel mathematical predictive tool, our findings highlight the possibility that GAGs may not have such an
accelerating effect on protein aggregation under the conditions existing in the basement membrane, given the values of
salt molarity and protein:GAG molar ratio existing under such conditions.
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Introduction
Aggregation of proteins in the form of extracellular amyloid
fibrils is a consistent mechanism underlying a group of diverse
human diseases, including neurodegenerative disorders and non-
neuropathic conditions [1]. These disorders differ for the type of
protein undergoing aggregation, for the type of organs involved in
amyloid deposition and, consequently, for the clinical profile
featured in each case. Among the most prominent neurodegen-
erative conditions are Alzheimer’s and Creutzfeldt-Jakob diseases,
which affect the central nervous system via extracellular deposits of
the amyloid b peptide and prion protein, respectively [1].
Examples of non-neuropathic conditions are light chain amyloid-
osis and hemodialysis-related amyloidosis, where deposits are
found in joints, skeletal tissue, heart, kidney, etc. In these two cases
the proteins involved are the immunoglobulin light chain and b2-
microglobulin, respectively [1].
Amyloid fibrils are often localized in close proximity to
basement membranes, a specialized component of the extracellu-
lar matrix that is mainly built of collagen and glycosaminoglycans
(GAGs) [2–4]. GAGs are long unbranched polysaccharides that
often occur as O- or N- linked side chains of proteoglycans, with
the exception of hyaluronic acid existing in a free form. Naturally
occurring GAGs include heparin, heparan sulfate, dermatan
sulfate, keratan sulfate, chondroitin sulfate and hyaluronic acid.
Other non-physiological derivatives of natural GAGs have been
used for studies in vitro, such as fully-O-desulfated heparin and
dextran sulfate [5–6]. GAGs have been found intimately
associated with all types of amyloid deposits in vivo so far analyzed
[7–14], leading to the hypothesis that they have fundamental
relevance in amyloidogenesis [2,4,15]. More importantly, GAGs
have been attributed an active role in amyloidogenesis, as they
display an ability to promote fibrillogenesis in vitro for a number of
protein or peptide systems [5,6,16–26]. The proteoglycan
perlecan, in particular, has been implicated as an important
factor determining amyloid fibril formation [2–4]. The active role
of GAGs and proteoglycans in amyloid fibril formation in vivo has
also been supported by the observation that inhibitors of heparan
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[27,28].
Studies on the effect of GAGs on amyloid fibril formation have
consisted so far on investigations focusing on a single protein, and
on one or a limited number of GAGs. This has allowed the effect
of one or more GAGs to be studied only on one particular system
and in well defined experimental conditions. Nevertheless, the
generic ability of GAGs to influence the process of amyloid fibril
formation, independently of the GAG used, protein studied and
solution conditions employed, encourages a systematic study using
a heterogeneous database reporting different GAGs and protein
systems and a variety of solution conditions. In this study we have
collected all the experimental data so far published on the effect of
GAGs on amyloid fibril formation in vitro. The data include
different GAGs, proteins and experimental conditions and have
been reported by different investigators. Using a number of single
parameter studies, as well as a multivariate analysis, we have
studied the database as a whole. We have identified the generic
chemical determinants responsible for the GAG-mediated accel-
eration of amyloid fibril formation, and have used this knowledge
to build a predictive equation of the effect of GAGs on protein
aggregation.
Methods
Data collection
Articles were collected from PubMed using the keywords
‘‘(protein OR peptide) AND (aggregation OR amyloid OR
fibrillation) AND (GAG OR glycosaminoglycan OR proteoglycan
OR heparin OR heparan)’’. Among the articles retrieved, only
those presenting both kinetic data of aggregation in vitro and a clear
explanation of the experimental conditions used to obtain such
data were kept for further analysis. Experimental conditions
include the nature and molar concentrations of the protein and
GAG, and the precise characteristics of the milieu (composition,
pH and temperature). Experiments performed in the presence of
additional parameters susceptible to have important effects on the
aggregation kinetics in the absence and in the presence of GAGs,
such as metal ions, were discarded.
We chose the aggregation half-time (t1/2), that is the time at
which the specific signal used to follow the aggregation reaction
reaches half of its final value, to describe the kinetics of protein
aggregation. t1/2 was preferred to the rate constant of elongation
(kagg) or the lag phase duration (tlag) because the latter parameter
cannot be compared in different experiments if the lag phase is
absent. When only kagg and tlag were mentioned in the article, we
used the following equation to calculate the t1/2 value [29]:
t1=2~tlagz
2
kagg
ð1Þ
For each set of experimental conditions, we calculated G, the
natural logarithm of the ratio between the t1/2 values in the
absence and in the presence of the GAG:
G~ln
t1=2 0 ðÞ
t1=2 GAG ðÞ

ð2Þ
Thus, if a GAG accelerates and decelerates the aggregation
process G is positive and negative, respectively. In the absence of a
lag phase, G is equal to Ln [kagg(GAG)/kagg(0)] (compare equations
1 and 2).
In cases where the authors of the original articles did not
mention any kinetic parameters, but showed only kinetic traces,
the in-house developed software plot2data was used to extract the
data. The software allows the user to map a Cartesian 2-D space
on a computer image containing a graph, in order to extracting
the coordinates of interesting points and making them available as
text values. The extracted data were then manually re-plotted, and
the resulting plots were fitted to equations 3 or 4, depending on the
absence or presence of a detectable lag phase, respectively [29]:
At~A?z A0{A? ðÞ e{tkagg ð3Þ
At~A0z
A?{A0
1ze
kagg t1=2{t
 ð4Þ
where A0, At and A‘ are the signal intensities of the techniques
used to monitor aggregation at time 0, t, and ‘, respectively. A0,
A‘, kagg and t1/2 were used as floating parameters in the procedure
of best fit.
The resulting dataset, summarizing the G values and
the corresponding experimental conditions in which they
where collected, is presented in Table S1 (see Supplementary
Information).
Multivariate analysis
For the multivariate analyses, G was set as the single dependent
variable. Different parameters describing the GAGs, polypeptide
chains and experimental characteristics were set as independent
variables. These include, for the GAG, the number of sulfates per
disaccharide unit, the number of negative charges per disaccharide
unit, the chemical nature of the uronic acid (iduronic or glucuronic
acid), the position of the sulfate (N- or O-sulfates), and the
molecular weight; they also include, for the protein, the length,
charge, composition in lysine and arginine residues, folding status
(globular or natively unfolded proteins) and association with
disease (disease-related or model proteins); finally they include the
solute molarity and the protein:GAG molar ratio for the
experimental conditions. All the independent variables that were
dichotomous (nature of the GAG uronic acid; position of the
sulfates on the GAG; folding status of the protein; protein
associated or not with disease) were recoded into dummy variables
and their interaction terms with other variables were taken into
account. We also systematically looked for the presence of possible
quadratic effects for each continuous variable.
The multivariate analyses were performed with the Microsoft
Excel add-on software PHStat2 [30], a tool that allows a
statistically coherent construction and optimization of multivariate
regression models. Both stepwise and best-subset model construc-
tion methods were used to reduce the number of significant
variables. The final model was the one that best fulfilled the
following characteristics: significance of each independent variable
(pvariable,0.05); significance of the model (pmodel,0.05); adjusted
coefficient of determination (R
2
adj) as close to 1 as possible; absence
of collinearity between the different independent variables,
detected with the variance inflation factor (VIF); homogeneous
distribution of the residuals (homoscedasticity).
Bootstrap and jackknife tests
Two statistical approaches were used to verify the significance
and robustness of the chosen model. In the bootstrap test 100
subsets of the original dataset comprising 39 entries were
GAG and Protein Aggregation
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sets, 26 entries each). Each of the 100 training sets was used to
perform the same multivariate analysis previously performed on
the whole dataset and to obtain a set of regression parameters.
Each of the resulting 100 sets was then used in the predictive
equation detailed below (equation 5, see results) to calculate G
values on the remaining subset of 1/3 entries (test set, 13 entries).
This led to the creation of 100 different sets of predicted and
observed G values, that were evaluated by linear regression
analysis to record correlation coefficients and p-values through
goodness of fit F-statistic.
In the jackknife test, single entries were systematically removed
from the full dataset of 39 entries and the multivariate analysis was
repeated on shortened datasets of 38 entries (for a total of 39 steps),
to obtain regression parameters with which we computed the
predicted G value for the removed entry using equation 5 (see
results). After the analysis was completed for the 39 removed
entries the 39 predicted G values were plotted against the
corresponding experimental values and the resulting plot was
analyzed by means of a linear regression.
Results
General strategy
The general strategy adopted for this study is presented in
Figure 1 (see also the Methods section). Briefly, experimental data
reporting the effect of GAGs on the kinetics of amyloid fibril
formation were collected from previously published articles using a
precise and rigorous method, after an extensive search of the
literature (Figure 1, step 1). The resulting dataset summarizes the
effects of different GAGs on the aggregation kinetics of different
proteins, together with the precise experimental conditions in
which these effects were recorded in each case (GAG and protein
types and concentrations; composition, ionic strength, total solute
concentration, pH and temperature of the milieu). The effect of a
GAG on protein aggregation was described by G, that is the
natural logarithm of the ratio between the aggregation half-time
t1/2 in the absence and in the presence of the GAG (see Methods).
The resulting dataset comprises 39 sets of data, representing 8
different proteins, 16 different GAGs and a variety of experimental
conditions (see Table S1 in Supplementary Information). The 8
proteins include both globular proteins, such as the immunoglob-
ulin light chain variable domain, and natively unfolded proteins,
such as a-synuclein. Some proteins are directly involved in disease,
such as the b-amyloid peptide, while others are model proteins,
like human muscle acylphosphatase. The 16 GAGs are either
existing GAGs from different families, such as heparin or
dermatan sulfate, or chemically modified GAGs such as fully
desulfated heparin or dextran sulfate.
To identify the determinants responsible for the accelerating
effects of GAGs on protein aggregation, we analyzed the influence
of different parameters on G. This was done by performing in
parallel single parameter fittings, through a search of correlations
between G and a variety of parameters analyzed one by one
(Figure 1, step 2a), and a multivariate analysis, that is a
combination of different parameters as independent variables in
a single equation to describe G as a function of all analysable
parameters simultaneously (Figure 1, step 2b). The parameters
that appeared from both step 2a and 2b to play a significant role
on the GAG-mediated acceleration of protein aggregation were
then combined into a single predictive equation yielding G as a
function of the key parameters only (Figure 1, step 3). Finally, the
validity and the robustness of the model and predictive equation
were assessed by statistical tests (Figure 1, step 4).
Single parameter analysis: characteristics of the GAGs
We first looked at the influence of the GAG sulfation state on G.
When the G value was plotted against the number of sulfate
moieties per GAG disaccharide unit for all the 39 entries of the
dataset, a significant linear positive correlation was observed
(Figure 2A, r=0.52, p=7.10
24). The analysis was repeated by
plotting average G values, where each average G value is the mean
of the G values related to the same sulfation state (Figure 2B).
Again, the average G value was found to correlate significantly
with the number of sulfates per disaccharide unit (Figure 2B,
r=0.97, p=0.001). To limit the complications arising from the
heterogeneity of proteins used in the study, we restricted the
analysis to a single protein type, i.e. a-synuclein (Figure 2C) and
the 173–243 fragment of gelsolin (Figure 2D), two polypeptides for
which enough data were available for a statistical analysis. The
correlation was found to be significant in both cases (Figure 2C,D,
r=0.89 and p=2.10
24 in both cases). The high significance of the
correlations shown in Figure 2A–D confirms the dependence of
the G value on the sulfate state of the GAG and suggests that the
sulfate moieties have comparable effects in the aggregation of the
various proteins analyzed. Importantly, in all cases the straight line
of best fit passes through the origin of the graph, where both the x
and y variables have values of 0. This observation indicates that in
the absence of sulfates the GAGs have no effects on the kinetics of
protein aggregation. While these data demonstrate that the
Figure 1. Scheme of the general strategy used in this study.
doi:10.1371/journal.pone.0011363.g001
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induced acceleration of protein aggregation, they also show that it
is not the only one, as GAGs with the same number of sulfate
groups per disaccharide units can have very different effects on
protein aggregation (Figure 2A).
We then looked at the importance of the GAG negative charge
in determining G (Figure 2E–H). The number of sulfates and the
number of negative charges per disaccharide unit of a GAG are
two highly correlated parameters, as each sulfate moiety brings 1
negative charge. However they are not identical, as most of the
GAGs have one additional negative charge per disaccharide unit
due to the presence of a carboxylate group. Significant correlations
were observed between the G value and the number of charges per
disaccharide unit whatever dataset was considered (Figure 2E–H).
The slopes of the lines of best fit were found to be identical when G
values are plotted versus the number of either sulfate moieties or
negative charges (Figure 2A–H). However, in the latter plots the
lines of best fit do not pass through the origins of the graphs, but
have G values of 0 when the number of negative charge is ca.1
(Figure 2E–H). This implies that the absence of effect on protein
aggregation is observed when the GAGs carry one negative charge
per disaccharide unit (i.e. only the carboxylate group) and no
sulfates. Therefore, the correlation between the G value and the
negative charge per disaccharide unit arises from the GAG
sulfation state, with the carboxylate group appearing to have no
effect.
The sulfate moieties in GAGs can be N- or O-sulfates. It has
been proposed that N- and O-sulfates can have different effects on
protein aggregation [31]. In our dataset, we did not observe any
significant difference between the effects of N- or O-sulfated GAGs
on protein aggregation kinetics (not shown). GAGs can also differ
in terms of the type of the hexuronic acid, which can be either
iduronic or glucuronic acid. It has been suggested that GAGs
containing iduronic acid could be more active, due to the greater
conformational flexibility of the iduronic pyranose ring with
respect to the glucuronic pyranose ring [32]. However, we could
not identify any significant difference between the effect of GAGs
with iduronic or glucuronic acid on protein aggregation, when
either all the data with the same GAG sulfation state were
considered (Figure 3A) or when the analysis was restricted to data
with the same sulfation state of GAG and only the 173–243
fragment of gelsolin as a polypeptide (Figure 3B). Finally, the G
value was not found to correlate with the molecular weight of the
GAG. Therefore, it seems that the sulfation state is the only GAG
characteristic that has a significant effect on the GAG-mediated
acceleration of amyloid fibril formation.
Single parameter analysis: characteristics of the proteins
In a second step, we studied the influence of different
parameters of the polypeptide chains. We looked at the effect of
the protein length, charge, and composition in lysine and arginine
residues, described in some cases to be responsible for GAG
binding [6,33]. We also divided the proteins of our dataset into
globular or natively unfolded proteins, or into disease-related or
disease-unrelated. We could not identify any significant correlation
between G and any of these parameters, with any of the dataset
used. This result could be due to the small number and
heterogeneity of proteins in the database.
Single parameter analysis: characteristics of the
experimental conditions
We thoroughly analyzed the importance of the experimental
conditions in determining the G value. Most of the experiments
reported in our dataset were carried out at physiological
temperature and pH, and under identical conditions of ionic
strength (see Table S1). As a consequence, the influence of these
three parameters could not be analyzed. To have an estimator of
buffer composition that could be used as a descriptive parameter
for our database, we analyzed the influence of the total solute
concentration of the buffer. A significant negative correlation was
found between the G value and the solute molarity when
considering the entire dataset (Figure 4A, r=0.47, p=0.003). A
higher solute molarity is associated with a less pronounced
accelerating effect of the GAG on protein aggregation
(Figure 4A). The analysis was repeated by plotting average G
values, each calculated over a range of solute molarity, for the
entire dataset; the analysis confirmed the presence of a correlation
(Figure 4B, r=0.84, p=0.04). In order to limit the problems
arising from the heterogeneity of the GAGs used, only data of the
GAG heparin were considered in a subsequent analysis. A
correlation was still observed when all G values obtained with
heparin were plotted against solute molarity (Figure 4C, r=0.63,
p=0.01), as well as when average G values, each calculated over a
range of solute molarity, were plotted versus solute molarity
(Figures 4D; r=0.73, p=0.09).
The next studied parameter was the ratio of molar concentra-
tions of the GAG and protein used in the experiments. A clear
positive correlation existed between the G value and the
Figure 2. Influence of the number of sulfates and negative charges per GAG disaccharide unit on protein aggregation. A–D:
dependence of the G value on the number of sulfates per GAG disaccharide unit; E–H: dependence of the G value on the number of negative charges
per GAG disaccharide unit; A and E: different GAGs, proteins and experimental conditions; B and F: idem, but each G value in the plot is the mean of
all the G values obtained with a GAG with the same number of sulfates or negative charges; C and G: only G data of a-synuclein in identical
experimental conditions are plotted; D and H: only G data of the 173–243 fragment of gelsolin in identical experimental conditions are plotted. In all
plots the solid lines represent the lines of best fit; the r and p values of the linear regression and the slope of the line of best fit are reported in each
plot.
doi:10.1371/journal.pone.0011363.g002
Figure 3. Influence of the chemical nature of the uronic acid
present in the GAG on protein aggregation. A: different GAGs,
proteins and experimental conditions; B: different GAGs, only the 173–
243 fragment of gelsolin in identical experimental conditions. In both
cases only GAGs with 2 sulfates per disaccharide unit are considered.
Experimental errors indicate standard deviations. The high p values
indicate lack of statistical significance.
doi:10.1371/journal.pone.0011363.g003
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r=0.49, p=0.002), average G values calculated over intervals of
protein:GAG molar ratio (Figure 5B, r=0.86, p=0.01), only G
values obtained with heparin (Figure 5C, r=0.76, p=0.001), or
only G values obtained with heparin and the 173–243 fragment of
gelsolin (Figure 5D, r=0.83, p=0.04). This finding shows that the
GAG becomes more effective in accelerating amyloid formation if
the concentration of protein grows more markedly than that of
GAG. The possible origin of such a correlation will be discussed in
the Discussion section.
Multivariate analysis and construction of a predictive
equation
We also performed a multivariate regression in parallel to, and
independently of, the single parameter analyses. The parameters
inserted in the multiparameter equations were the same as those
analyzed individually. Thus, as far as the GAG is concerned, we
considered the number of sulfate groups per disaccharide unit, the
number of negative charges per disaccharide unit, the chemical
nature of the uronic acid (iduronic or glucuronic acid), the type of
the sulfate moiety (N- or O-sulfation) and the molecular weight for
the GAG. As far as the protein is concerned, we took into account
the protein length, net charge, composition in lysine and arginine
residues, folding status (globular or natively unfolded proteins) and
association with disease (disease-related or disease-unrelated).
Finally, we considered for the experimental conditions the solute
molarity and the protein:GAG molar ratio. The multivariate
regression was allowed to run on the entire dataset. The best
model that fitted the experimental data was the following (see
Methods for the definition of the best model):
G~y0zaPSzbPBzcPMRzc0 PMR ðÞ
2 ð5Þ
where PS is the number of sulfate groups per disaccharide unit, PB
is the total molarity of the solutes in mM units, PMR is the
protein:GAG molar ratio and y0 is the y axis intercept. a, b, c and
c9 are the multiplying factors of the various parameters and were
left free to float in the fitting procedure, similarly to y0. The
Figure 4. Influence of solute molarity on the GAG-mediated acceleration of amyloid fibril formation. A and B, different GAGs, proteins
and experimental conditions; C and D, only heparin, different proteins, different experimental conditions; A and C, all G values; B and D, mean values
of G, each calculated at a defined solute molarity range. In all plots the solid lines represent the lines of best fit; the r and p values of the linear
regression and the slope of the line of best fit are reported in each plot.
doi:10.1371/journal.pone.0011363.g004
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20.01660.004, 0.1160.03 and 20.002060.0005, for y0,a ,b ,c
and c9, respectively. Note that this model includes a quadratic
effect of the protein:GAG molar ratio. Models that did not
consider this quadratic effect, i.e. where the c9(PMR)
2 term was
absent, were much less accurate in fitting to the experimental data.
The model resulting from the multivariate analysis is highly
significant. All the coefficients of the single variables have a
significance lower than 10
23; the significance of the whole model
is equal to 2.10
26; the adjusted R
2 value of the model is equal to
0.74, indicating that 74% of the variance observed in the
experimental dataset is explained by this simple model. Finally,
we performed bootstrap and jackknife tests that verified
the robustness of the model and its independence of the
dataset composition (see Figures S1 and S2 in Supplementary
Information).
The results of the multivariate analysis have two main
implications. First, it confirms the significance of the three
parameters identified with the single parameter analyses in
determining the GAG-mediated acceleration of amyloid fibril
formation: the sulfation state of the GAG, the molarity of the
solutes, and the protein:GAG molar ratio. Second, it confirms that
all the other parameters studied in the single parameter analyses
do not have a similar importance and appear to be non-significant
altogether (probably as a result of the small number of entries in
our dataset, at least in some cases).
Finally, we used equation 5 to predict G based solely on the
knowledge of the sulfation state of the GAG, the molarity of the
solutes, and the protein:GAG molar ratio, for the 39 entries of the
dataset (Figure 6). The values of G predicted by equation 5
correlate significantly with those measured experimentally, as
shown in Figure 6A (r=0.86; p,10
25). The residuals between the
G values observed experimentally and those predicted by equation
5 are small and randomly distributed around 0, confirming the
validity of the model (Figure 6B).
Discussion
In this work we have used previously published data to build a
large database containing the effects of various GAGs on the rate
of amyloid fibril formation by different proteins and in different
solution conditions. The aim was to identify and rationalize the
Figure 5. Influence of the protein:GAG molar ratio on amyloid fibril formation. A, different GAGs, proteins and experimental conditions; B,
idem but the mean values of G, each obtained at a given protein:GAG molar ratio interval; C, only heparin, different proteins, different experimental
conditions; D, only heparin, only the 173–243 fragment of gelsolin, different experimental conditions. In all plots the solid lines represent the lines of
best fit; the r and p values of the linear regression and the slope of the line of best fit are reported in each plot.
doi:10.1371/journal.pone.0011363.g005
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process of amyloid fibril formation. We have adopted two different
and complementary methods for identifying such factors: a set of
single parameter analyses and a multivariate analysis. Using this
approach, we have identified three major determinants of the
effect of GAGs on the kinetics of amyloid formation: the sulfation
state of the GAG, the molar concentration of all compounds
present in the buffer, and the protein/GAG molar ratio. It is
highly significant that the two strategies have identified the same
parameters, reinforcing the conclusions. The results do not rule
out the importance of additional factors, particularly those arising
from the chemical nature and structure of the protein undergoing
aggregation. However, our statistical approach could not identify
any of such determinants, most probably because of the limited
size of our database.
The importance of the GAG sulfation state
It has been previously pointed out that the sulfation state of a
GAG is an important determinant of the ability of the
polysaccharide to promote or accelerate amyloid fibril formation
[5,6,18,22,23,34,35]. A correlation between the sulfation state of
the GAG and the extent of the amyloid formation acceleration has
been observed using various systems, including the islet amyloid
polypeptide [18], the amyloid b peptide [35], b2-microglobulin
[36], the 173–243 fragment of gelsolin [5], a-synuclein [6] and an
immunoglobulin light-chain variable domain [23]. However, in all
these cases it has not been possible to distinguish between the
sulfation state and the charge state (also involving the carboxylate
group of the GAG), leading some investigators to emphasize, more
generally, the importance of the charge state of the GAG rather
than of the sulfation state [18,36]. Moreover, in previous studies it
has not been possible to clarify whether the backbone of the
polysaccharide plays a role in the GAG-protein interaction. Our
observation that the GAG-induced acceleration disappears when
the sulfation state is zero indicates that neither the carboxylate
moiety, nor the backbone of the polysaccharide play relevant roles
in the effect of GAGs on amyloid formation.
In addition, our comparison between GAGs containing
iduronic and glucuronic acids has showed no significant
differences, indicating that the configuration of the chiral carbon
5 bearing the carboxylate group in the uronic acid residue has no
apparent importance in determining the effect of the GAG.
Similarly, no differences have been observed when comparing O-
and N-sulfates. The finding that sulfate moieties play a role due to
their high density and their regular distribution on the polysac-
charide surface [37] indicates that the distinction between N- and
O-sulfation might not be a fundamental one.
Finally, we have not observed any effect of the GAG molecular
weight. It should be noticed that we have considered only
polysaccharides with a sufficiently high length. Oligosaccharides
shorter than 6 or 8 disaccharide units have been shown to have a
lower effect on protein aggregation than longer GAGs [29,37,38].
Thus, it appears that the GAG loses its effect only below a well
defined threshold, when the excessively small length of the
polysaccharide chain suppresses the macromolecular nature of
the GAG.
The ratio of protein to GAG concentration as a critical
factor
One of the clearest result of our analysis is a strong dependence
of the accelerating effect of the GAG on the respective protein and
GAG molar concentrations. This parameter is ignored in all
studies aimed at investigating the effect of GAGs on protein
aggregation and could explain some discrepancies observed
between different sets of experiments, for example those involving
a-synuclein [6,39].
The correlation observed in the single parameter analysis implies
that an excess of GAG decreases its accelerating effect on protein
aggregation. The multivariate analysis indicates the existence of a
negative quadratic component, in addition to a positive linear
component, in the dependence of the acceleration of protein
aggregation on the protein:GAG molar ratio. This result translates
into a bell-shape dependence of the acceleration on the protein:
GAG molar ratio. In such a dependence the effect of GAG on
protein aggregation is maximal at a given protein:GAG molar ratio.
At lower or higher values of the protein:GAG molar ratio the GAG
has a lower effect on protein aggregation. From the collected
experimental data and the resulting multivariate analysis we can
Figure 6. Prediction of the effect of GAGs on amyloid fibril formation using the predictive equation 5. A, Predicted values of G plotted
versus those observed experimentally. The solid line represents the straight line of best fit; the r and p values of the linear regression and the slope of
the line of best fit are reported in the plot. B, Residuals between G values observed experimentally and predicted plotted versus the G values
observed experimentally. The solid line represents the mean of the residuals.
doi:10.1371/journal.pone.0011363.g006
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molecules. The descending arm of the dependence – a decreased
effectwhentheGAGconcentrationincreases– couldoriginatefrom
the ability of the GAG molecules to sequester protein molecules at
different and distant sites, hindering their effective interaction and
aggregation. Importantly,most of theexperimental data reported so
far in the literature and collected here were performed in the
descending arm, i.e. at high GAG concentrations (see Figure 5 and
Table S1 in Supplementary Information).
At the high concentration of GAGs and at the relatively low
concentration of soluble, non-fibrous proteins populating the
basement membrane of the extracellular matrix, where amyloid
fibril formation occurs in pathology, GAGs may have an effect
much lower than previously thought, without producing a
remarkable acceleration of amyloid fibril formation. In such
conditions of low protein:GAG molar ratio, protein aggregation
still occurs in proximity of the GAGs, given the high affinity of
such compounds for proteins, but the polysaccharides may have a
neutral effect, rather than an accelerating potential. On the other
hand, a high local concentration of peptide/protein may occur at
the sites at which it is secreted. This issue deserves further analysis.
The importance of the solute molarity
Another result emerging from our analysis is that the ability of
GAGs to accelerate amyloid fibril formation correlates negatively
with the molarity of the compounds composing the buffer solution.
Such a negative correlation, which has already been reported on
isolated systems [20,40–42], is shown here to be a generic
phenomenon of the protein-GAG interaction. The dependence of
the GAG-mediated acceleration of protein aggregation on the
solute molarity can originate from two non-exclusive phenomena.
It first reveals that the interactions between GAGs and proteins are
in part electrostatic, as these interactions are shielded by high salt
concentrations. It could also be due to the release of the GAG
positive counterion upon protein binding, with such a release
being entropically favored by a low ionic strength buffer [43,44].
Intriguingly, at the salt concentrations existing in the human
extracellular fluids amyloid fibril formation seems to be unaffected
or only weakly affected by GAGs (see Figure 4). This observation
reinforces the aforementioned possibility that under the conditions
found in the basement membrane of the extracellular matrix
GAGs may not have that dramatic accelerating effect on protein
aggregation.
Conclusions
The three parameters identified here using both single
parameter and multivariate analyses have been combined into a
single predictive equation of the effect of GAGs on the kinetics of
amyloid formation. The equation accounts for L of the observed
experimental variability in the observed acceleration, with the
remaining J arising from other characteristics that are yet
unidentified. Such unidentified factors could be inherent structural
and/or sequence-based characteristics of the protein, as well as
other determinants of the environment or of the GAG structure.
The further improvement of our mathematical tool awaits
accumulation of experimental data on larger sets of proteins,
GAGs and conditions.
It is still remarkable, however, to have achieved a predictive
mathematical tool that can determine, with reasonable accuracy,
the effect of a given GAG on the amyloid fibril formation process
of a given protein and under well-defined experimental conditions.
Albeit important, the outcome of the analysis is not limited to the
obtainment of a predictive algorithm. It has identified previously
neglected factors as important determinants of the GAG-mediated
acceleration of protein aggregation, such as solute molarity and
protein:GAG molar ratio. The analysis has highlighted that a
GAG is not necessarily pro-aggregating, but can rather have
different effects depending on the conditions, and has showed that
under the conditions existing in the basement membrane of the
extracellular matrix, where amyloid structures deposit in pathol-
ogy, GAGs can have little effect on the process of amyloid fibril
formation.
Supporting Information
Figure S1 Results from the bootstrap test. The dataset was
randomly subsampled generating 100 training sets (containing 2/3
of the data corresponding to 26 entries) and 100 test sets
(containing the remaining 1/3 of the data corresponding to 13
entries). Each training set was subjected to multivariate analysis as
described for the full dataset (see Methods) to generate a predictive
equation with its own set of parameters, that was then applied to
the corresponding test set to obtain G values predictions. The 100
bootstrap tests performed are represented on the x axis. The closed
circles indicate the p values of the 100 model predictive equations
built from the training sets (the scale is reported on the left y axis).
The open circles indicate the p-values of the regressions obtained
plotting predicted versus observed G values for the 100 test sets.
The mean and associated standard error values of the Pearson
coefficients associated to the p-regression values are
R=0.78960.008, indicating that the model we built was robust
in term of dataset composition.
Found at: doi:10.1371/journal.pone.0011363.s001 (0.54 MB TIF)
Figure S2 Results from the jackknife test. For each of the 39
data of our dataset, the predicted G value was calculated applying
the predictive equation generated by the multivariate regression
analysis on a dataset composed of the 38 remaining data (see
Methods). The graph shows the linear correlation analysis between
the 39 predicted vs experimental G values, giving a significant
correlation with an R
2=0.59 (p-value,10
25).
Found at: doi:10.1371/journal.pone.0011363.s002 (0.36 MB TIF)
Table S1 Database of the effects of GAGs on the kinetics of
protein aggregation, constructed from the literature.
aDummy
variables. The binary code indicated is the one used for the
multivariate analyses.
bProtein net charge calculated at pH7.5.
References: Calamai et al (2006) Biochemistry 45:12806 -
Cohlberg et al (2002) Biochemistry 41:1502 - McLaughlin et al
(2006) Protein Sci 15:1710 - McLaurin et al (1999) Eur J Biochem
266:1101 - Shuvaev and Siest (2000) Neurosci Lett 280:131 - Suk
et al (2006) Biochemistry 45:2234 - Takase (1998) FEBS Lett
441:271 - Uversky et al (2005) Brain Res Mol Brain Res 134:84.
Found at: doi:10.1371/journal.pone.0011363.s003 (0.06 MB
PDF)
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